PMID- 24618042
OWN - NLM
STAT- MEDLINE
DCOM- 20141126
LR  - 20211021
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Print)
IS  - 1044-5323 (Linking)
VI  - 26
IP  - 2
DP  - 2014 Apr
TI  - Clinical utility of natural killer cells in cancer therapy and transplantation.
PG  - 161-72
LID - S1044-5323(14)00015-3 [pii]
LID - 10.1016/j.smim.2014.02.002 [doi]
AB  - Natural killer (NK) cells recognize deranged cells that display stress receptors 
      or loss of major histocompatibility complex (MHC) class I. During development, NK 
      cells become "licensed" only after they encounter cognate human leukocyte antigen 
      (HLA) class I, leading to the acquisition of effector function. NK cells can be 
      exploited for cancer therapy in several ways. These include targeting with 
      monoclonal antibodies alone or combined with ex vivo and in vivo NK cell 
      activation to facilitate adoptive immunotherapy using donor-derived NK cell 
      products to induce graft-vs-tumor effects. In the adoptive transfer setting, 
      persistence and in vivo expansion requires lymphodepleting chemotherapy to 
      prevent rejection and provide homeostatic cytokines (such as IL-15) that activate 
      NK cells. IL-15 has the advantage of avoiding regulatory T-cell expansion. 
      Clinical applications are currently being tested. To enhance in vivo expansion, 
      IL-2 has been used at low doses. However, low dose administration also leads to 
      the stimulation of regulatory T cells. Monoclonal antibodies and bispecific 
      killer engagers (BiKEs) may enhance specificity by targeting CD16 on NK cells to 
      tumor antigens. Inhibition of CD16 shedding may also promote enhanced 
      cytotoxicity. Future strategies include exploiting favorable donor immunogenetics 
      or ex vivo expansion of NK cells from blood, progenitors, or pluripotent cells. 
      Comparative clinical trials are needed to test these approaches.
CI  - Copyright (c) 2014 Elsevier Ltd. All rights reserved.
FAU - Knorr, David A
AU  - Knorr DA
AD  - Blood and Marrow Transplant Program, Department of Medicine, University of 
      Minnesota, Minneapolis, MN 55455, United States.
FAU - Bachanova, Veronika
AU  - Bachanova V
AD  - Blood and Marrow Transplant Program, Department of Medicine, University of 
      Minnesota, Minneapolis, MN 55455, United States.
FAU - Verneris, Michael R
AU  - Verneris MR
AD  - Blood and Marrow Transplant Program, Department of Medicine, University of 
      Minnesota, Minneapolis, MN 55455, United States; Department of Pediatrics, 
      University of Minnesota, Minneapolis, MN 55455, United States.
FAU - Miller, Jeffrey S
AU  - Miller JS
AD  - Blood and Marrow Transplant Program, Department of Medicine, University of 
      Minnesota, Minneapolis, MN 55455, United States. Electronic address: 
      mille001@umn.edu.
LA  - eng
GR  - KL2 TR000113/TR/NCATS NIH HHS/United States
GR  - P01 CA065493/CA/NCI NIH HHS/United States
GR  - P01 CA111412/CA/NCI NIH HHS/United States
GR  - UL1 TR000114/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20140305
PL  - England
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
SB  - IM
MH  - Cell- and Tissue-Based Therapy/methods
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Killer Cells, Natural/cytology/*immunology/metabolism/*transplantation
MH  - Neoplasms/*immunology/*therapy
PMC - PMC3984606
MID - NIHMS566650
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Adoptive cell therapy
OT  - Immunomodulation
OT  - Immunotherapy
OT  - NK cells
EDAT- 2014/03/13 06:00
MHDA- 2014/12/15 06:00
PMCR- 2015/04/01
CRDT- 2014/03/13 06:00
PHST- 2014/01/22 00:00 [received]
PHST- 2014/01/30 00:00 [revised]
PHST- 2014/02/04 00:00 [accepted]
PHST- 2014/03/13 06:00 [entrez]
PHST- 2014/03/13 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - S1044-5323(14)00015-3 [pii]
AID - 10.1016/j.smim.2014.02.002 [doi]
PST - ppublish
SO  - Semin Immunol. 2014 Apr;26(2):161-72. doi: 10.1016/j.smim.2014.02.002. Epub 2014 
      Mar 5.